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ABSTRACT
Objective: Malaria is a parasitic infection that causes worldwide health problems. The absence of an effective vaccine and Plasmodium strains that are 
resistant to antimalarial drugs emphasize the importance of developing new chemotherapeutic agents. The use of computers for in-silico screening, or 
virtual screening, is currently being developed as a method for discovering antimalarial drugs. One of the enzymes that can support the development 
of the malaria parasite is the Plasmodium falciparum enoyl-acyl carrier protein reductase (PfENR). Inhibition of these enzymes leads to Type II lipid 
biosynthesis inhibition on the parasite.
Methods: This research investigates the use of virtual screening to find PfENR inhibitor candidates. A molecular docking method using GOLD software 
and the medicinal plants in Indonesia database will be used. This target has been optimized by the removal of residues and the addition of charge. 
Ligand is expected to be an inhibitor of PfENR.
Results: In-silico screening, or virtual screening, found that the top five compounds with the highest GOLD score at trial are kaempferol 3-rhamnosyl-
(1-3)-rhamnosyl-(1-6)-glucoside; cyanidin 3,5-di-(6-malonylglucoside); 8-hydroxyapigenin 8-(2’’, 4’’-disulfato glucuronide); epigallocatechin 3,5,-di-
O-gallat; quercetin 3,4’-dimethyl ether 7-alpha-L-arabinofuranosyl-(1-6)-glucoside. They had GOLD scores of 94.73, 95.90, 86.46, 85.39, and 84.40, 
respectively.
Conclusions: There are two candidate inhibitor compounds from tea (Camellia sinensis), which have potential for development as an antimalarial 
drug, which are kaempferol 3-rhamnosyl-(1-3)-rhamnosyl-(1-6)-glucoside and epigallocatechin 3,5,-di-O-gallate, with a GOLD score of 94.73 and 
85.39, respectively.
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INTRODUCTION
Malaria is one of the most serious parasitic infections in the world. 
There are more than 500 million cases of malaria per year, with about 
3 million deaths. A total of 40% of the world’s population is living in 
malaria-endemic areas and Indonesia, 35% of the population live in 
areas at risk of malaria [1]. Malaria is the cause of hemolytic anemia due 
to infection of red blood cells by a protozoan of the genus Plasmodium 
transmitted to humans through the saliva of female Anopheles 
mosquitoes [2]. Four Plasmodium species cause malaria: Plasmodium 
falciparum, Plasmodium ovale, Plasmodium malariae, and Plasmodium 
vivax. Of these, four parasite species, P. falciparum is the source of the 
most severe and often fatal forms of the disease, tropical malaria, and 
cerebral malaria [3].
Antimalarial drugs, that are effective, safe, practical to use, and 
economically affordable are essential for reducing malaria deaths. 
Medications such as quinine, chloroquine, quinidine, mefloquine, and 
artemisinin derivatives are effective and work quickly; however, the 
problem, the world is facing today is parasite resistance to antimalarial 
drugs [1]. There are several possible reasons for malaria parasites 
to become resistant to antimalarial drugs like chloroquine. First, the 
parasite does not have an active site to bind with chloroquine, so 
this drug cannot be concentrated in the red blood cells; furthermore, 
resistant Plasmodium has other biochemical pathways which no 
heme involvement in the process to synthesize amino acids, and thus, 
avoid the influence of chloroquine. Chloroquine binds to heme in red 
blood cells forming the complex which is highly toxic resulting cell 
lysis and parasite autodigestion. Chloroquine is required in sufficient 
concentration in the red blood cells to act as antimalarial drug. 
A second cause of resistance is the parasite’s ability to spontaneously 
mutate under drug stress [4].
New, antimalarial drug development is essential to controlling 
malaria. To achieve this goal, identification of targets and compounds 
for inhibiting malaria treatment is needed [5]. In the last decade, 
considerable potential targets for antimalarials have been found. One 
general target includes pathways of Type II fatty acid biosynthesis, 
with a specific target, P. falciparum enoyl-acyl carrier protein reductase 
(PfENR), an enzyme that plays a significant role in Type II fatty acid 
biosynthesis of P. falciparum. PfENR catalyzes the last step of the 
elongation cycle of fatty acid biosynthesis and works by reducing 
the carbon double bond in the covalently bonded the acyl carrier 
protein [6,7]. The discovery of inhibitors of Type II fatty acid synthesis 
in the P. falciparum is expected to shorten the life cycle of the parasite. 
Terminations of biosynthetic pathways in the Plasmodium cause loss 
of the energy needed to perform metabolic processes and causing this 
organism to slowly die.
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Advances in information technology today can offer alternatives 
to the search for new drugs. Therefore, screening methods used 
at an early stage in the search for drug candidates have been 
developed using computer technology. In this study, the screening 
process was conducted using virtual screening or in-silico 
(computer simulation). In-silico screening is a computing system or 
analog in-silico in biological screening. The purpose of in-silico 
screening is to look for value and rank or filter a set of data 
structures using one or more computational procedures. In-silico 
screening is used to help determine which compounds will 
be screened or help for the process of synthesis [8].PTMDS 2017 | The 1st Physics and Technologies in Medicine and Dentistry Symposium




Materials used in this study include three-dimensional (3D) structures 
of macromolecules, PfENR downloaded from the Protein Data Bank 
(http://www.rscb.org.pdb, PDB id: 1NHG), which binds to nicotinamide 
adenine dinucleotide and triclosan (TCL); the 3D structure of the ligand 
on the database of medicinal plants in Indonesia; and the positive and 
negative controls as PfENR inhibitor. PfENR, which is used for molecular 
docking targets, should be separated from the solvent and ligand or 
non-standard residues. Separation of molecules that are not required 
is done using the UCSF Chimera program. The results will be used for 
docking, which is then stored in the pdb format.
PfENR 3D structure optimization is performed using Vega ZZ software. 
Optimization includes the elimination of water molecules, the addition 
of a hydrogen atom, and repair charge by adding a Gasteiger partial 
charge, giving AutoDock force field, and the application of minimization. 
Macromolecule minimization is done in two stages, i.e., the 100-steps 
steepest descent method, followed by the 1000 steps of conjugate 
gradients. Validation of virtual screening methods, or in-silico screening, 
was done by molecular docking. The structures of positive control 
(diazaborine and TCL) and negative control (ethionamide and isoniazid) 
are downloaded from http://pubchem.ncbi.nlm.nih.gov/and then 
perform the molecular docking optimization using the GOLD software.
Ligands used in this study were obtained from the database of medicinal 
plants in Indonesia [9], and totaled as many as 1450 in the form of 3D 
ligands with the Tripos/Sybyl mol2 format. Ligands were optimized using 
Vega ZZ software with the addition of hydrogen and energy minimization. 
Molecular docking of ligands from the Indonesian medicinal plants 
database with target molecules PfENR was performed with GOLD 
software. Molecular docking resulted in obtaining the top five ranking 
compounds according to the highest GOLD score. Ranked candidate 
inhibitor compounds were visualized using GOLD software and PyMOL.
RESULTS AND DISCUSSION
PfENRs have a specific sequence, beginning with the insertion of 43 
amino acid residues on one strand that is not owned by other ENR 
species. This enzyme also has a complex area which is low in residues, 
between 325 and 367, which is surrounded by polar residues such 
as asparagine, lysine, glutamine, and serine [10]. The PfENR crystal 
structure shows that hydrophobic residues surround the active site: 
Val222, Tyr277, Tyr267, Phe368, Pro314, Gly313, Leu315, His214, 
Ala217, Asn218, Ala219, Lys220, Met231, and Lys285 [11].
To validate the virtual screening method to be used, the molecular 
docking with positive and negative control using genetic algorithms 
(GA) was run with several search option speeds, i.e. fast, medium, and 
slow (Table 1). Positive control showed better results compared to 
the negative control from the docking to PfENR. Each speed GA search 
option is performed five times per molecular docking. Coordinates used 
for docking space will also be used on the molecular docking in virtual 
screening. Coordinates obtained for the docking space coordinates (X, 
Y, Z) are 51.24, 93.77, and 34.53, respectively.
Based on the results of in-silico screening, the top five compounds 
with the highest occurrence at trial were kaempferol3-rhamnosyl-(1-
3)-rhamnosyl-(1-6)-glucoside; cyanidin 3; 5-di-(6-malonylglucoside); 
8-hydroxyapigenin 8-(2’’, 4’’-disulfato glucuronide); epigallocatechin 
3,5,-di-O-gallat; and quercetin 3,4’- dimethyl ether 7-alpha-L-
arabinofuranosyl-(1-6)-glucoside with GOLD scores of 94.73, 95.90, 
86.46, 85.39, and 84.40, respectively. GOLD score results showed the 
best position of PfENR inhibitor compounds compared with affinity 
energy. GOLD score assessment results are negative results from the 
sum of all energy, so that the greater the score, the better the bond [12]. 
Virtual screening results had many interactions with PfENR active site, 
that is, kaempferol 3-rhamnosyl-(1-3)-rhamnosyl-(1-6)-glycoside, and 
epigallocatechin 3,5,-di-O-gallate visualized and analyzed with using 
the GOLD program and PyMOL.
Kaempferol 3-rhamnosyl-(1-3)-rhamnosyl-(1-6)-glucoside showed a 
hydrogen bond with Leu315, Gly313, Leu265, and Gly106. Hydrogen 
bonding in the active site is due to hydrophobic interactions amplified by 
one or more hydrogen bonds. Hydrophobic interactions can be formed due 
to the active site PfENR surrounded by hydrophobic residues while the 
hydrogen bonds formed by amino acid residues electronegative groups 
such as-OH and O29 and O44. Kaempferol 3-rhamnosyl-(1-3)-rhamnosyl-
(1-6)-glucoside has a hydrogen binding between the hydroxyl group to 
the nitrogen and oxygen O29 at residue Leu315 at a distance of 2.339 Å 
and 2.875 Å, and 2.917 Å to Gly313 (Fig. 1). Residues Gly313 and Leu315 
are located in a nicotinamide-binding pocket, thus binding on this residue 
leads to inhibition of the binding of the enzyme [10]. These barriers affect 
the substrate of PfENR that cannot occupy the active site of the enzyme.
Kaempferol 3-rhamnosyl-(1-3)-rhamnosyl-(1-6)-glucoside compound 
is a flavanol glycoside derived from the family of Theaceae plant species 
origin, i.e., Camellia sinensis, Camellia bohea, Camellia theifera, Thea 
sinensis, Thea assamica, Thea cochinchinensis, Thea cantoniensis, better 
known as tea. Flavonoids are known to have antibacterial activity, 
and some flavonoids have antimalarial activity [13]. Discovery and 
development of flavonoids as an antimalarial has been developed over 
the last few years [13,14].
Besides containing kaempferol 3-rhamnosyl-(1-3)-rhamnosyl-(1-6)-
glucoside, tea also contains a compound epigallocatechin 3,5,-di-O-
gallate. Sannella et al. [14] stated in his study that the catechins content 
in tea, especially epigallocatechin-3-gallate and epicatechingallate, have 
inhibitory activity on the growth of P. falciparum in vitro. Another study 
states that tea catechin has the same potential as the binding of TCL 
with PfENR. Epigallocatechingallate has strong binding with PfENR, to 
form a binary complex conformation [15].
Epigallocatechin 3,5,-di-O-gallate shows the hydrogen binding of 
electronegative groups such as OH on O16, O31, and O47 with Gly313, 
Tyr277, Asn218, with distances between 2.5 and 3.5 Å (Fig. 2). Similar 
to kaempferol 3-rhamnosyl-(1-3)-rhamnosyl-(1-6)-glucoside, which 
has the nicotinamide-binding pocket, epigallocatechin 3,5,-di-O-gallate 
also binds with Gly313 and Leu315 so it can inhibit the binding of the 
Table 1: Average score of binding affinity (GOLD score) of 
positive control and negative control with PfENR from docking 
experiment with GOLD software
Control Fast Medium Slow
Positive control
Diazaborine 45.38 48.82 50.24
Triclosan 43.09 43.49 43.59
Negative control
Ethionamide 35.36 36.19 36.44
Isoniazid 31.86 32.63 32.55
PfENR: Plasmodium falciparum enoyl-acyl carrier protein reductase
Fig. 1: Interaction of kaempferol 3-rhamnosyl-(1-3)- rhamnosyl-
(1-6)-glucoside (blue) with some amino acid residues (purple) on 
Plasmodium falciparum enoyl-acyl carrier protein reductase
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substrate with the enzyme. This obstacle cannot make the enzyme 
work to catalyze reactions in the process of extending the synthesis of 
fatty acids on P. falciparum.
CONCLUSION
Based on the results of in-silico screening using the medicinal plants 
in Indonesia database against targets PfENR, there are two potential 
candidates of chemical compounds from tea (C. sinensis) that have 
prospects as inhibitors: The chemical compounds kaempferol 
3-rhamnosyl-(1-3)-rhamnosyl-(1-6)-glucoside and epigallocatechin 
3,5,-di-O-gallate, with a GOLD score of 94.73 and 85.39, respectively.
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Fig. 2: Interaction of epigallocatechin 3,5,-di-O-gallate (blue) with 
some amino acid residues (green) in Plasmodium falciparum 
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